A Global Phase III study of BW-20805
Latest Information Update: 01 Apr 2026
At a glance
- Drugs BW 20805 (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
Most Recent Events
- 01 Apr 2026 New trial record
- 16 Mar 2026 According to Argo Biopharmaceutical media release, company plans for a global Phase III study in second half of 2026.